Results 311 to 320 of about 1,162,311 (403)

A Poly (β‐Amino Esters)‐Based Multicomponent Nanoparticle for Efficient mRNA Delivery to Acute Myeloid Leukemia Cells

ChemistryEurope, EarlyView.
A structurally engineered nonviral vector (poly (β‐amino esters)‐lipid‐palmitic anhydride nanoparticles) integrates a poly(β‐amino ester) core for mRNA binding, palmitic anhydride for enhancing cellular uptake, and cationic 1,2‐Dioleoyl‐3‐trimethylammonium‐propane lipid for endosomal disruption is developed, which achieves 64.4% transfection efficiency
Zheng Wang, Dehua Huang, Lanrong Wu, Yuheng Cao, Yejun Zhang, Chunyan Li, Jiang Jiang, Guangcun Chen, Qiangbin Wang   +8 more
wiley   +1 more source

Dynamic Changes of Immunoreactive CD34, CD117, and CD41 Hematopoietic Stem Cells in Human Placentas of Different Gestational Ages. [PDF]

J Dev Biol
Jovicic S, Nikolic IR, Amidžić L, Ljubojevic V, Barudzija M, Skrbic R.   +5 more
europepmc   +1 more source

The purification and characterization of fetal liver hematopoietic stem cells.

, 1995
Sean J. Morrison, Houman D. Hemmati, Antoni M. Wandycz, Irving L. Weissman   +3 more
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Niche-derived Semaphorin 4A safeguards functional identity of myeloid-biased hematopoietic stem cells. [PDF]

Nat Aging
Toghani D, Gupte S, Zeng S, Mahammadov E, Crosse EI, Seyedhassantehrani N, Burns C, Gravano D, Radtke S, Kiem HP, Rodriguez S, Carlesso N, Pradeep A, Georgiades A, Lucas F, Wilson NK, Kinston SJ, Göttgens B, Zong L, Beerman I, Park B, Janssens DH, Jones D, Toghani A, Nerlov C, Pietras EM, Mesnieres M, Maes C, Kumanogoh A, Worzfeld T, Cheong JG, Josefowicz SZ, Kharchenko P, Scadden DT, Scialdone A, Spencer JA, Silberstein L.   +36 more
europepmc   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Repurposing of an inotropic drug dobutamine to enhance the production of human hematopoietic stem cells from human induced pluripotent stem cells. [PDF]

Stem Cell Res Ther
Laowtammathron C, Srisook P, Kheolamai P, Parnpai R, Lorthongpanich C, Issaragrisil S.   +5 more
europepmc   +1 more source

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, EarlyView.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. [PDF]

Cell Rep Med
Conti A, Giannetti K, Midena F, Beretta S, Gualandi N, De Marco R, Carsana E, Varesi A, Tavella T, Alessandrini L, Zarghamian P, Weber A, Ferrari S, Brombin C, Gilioli D, Della Volpe L, Xie SZ, Merelli I, Cathomen T, Naldini L, Di Micco R.   +20 more
europepmc   +1 more source